JP6949952B2 - スピロ環化合物 - Google Patents
スピロ環化合物 Download PDFInfo
- Publication number
- JP6949952B2 JP6949952B2 JP2019518440A JP2019518440A JP6949952B2 JP 6949952 B2 JP6949952 B2 JP 6949952B2 JP 2019518440 A JP2019518440 A JP 2019518440A JP 2019518440 A JP2019518440 A JP 2019518440A JP 6949952 B2 JP6949952 B2 JP 6949952B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- salt
- compound
- compound according
- acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*(C([C@]1C*(CC(*(CC2)CC=C2c(cc2)ccc2C(OC(*C)=O)=*)=O)CC1)=O)c1cc(C(c(cc2N(C)CC)ccc2C#*)=*)c(*(C)C)cc1 Chemical compound CC*(C([C@]1C*(CC(*(CC2)CC=C2c(cc2)ccc2C(OC(*C)=O)=*)=O)CC1)=O)c1cc(C(c(cc2N(C)CC)ccc2C#*)=*)c(*(C)C)cc1 0.000 description 3
- KZDGDUSDTLBCJE-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N KZDGDUSDTLBCJE-SSEXGKCCSA-N 0.000 description 1
- IWRIHOVBGLAUMI-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1ccc(C(F)(F)F)c(C#N)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1ccc(C(F)(F)F)c(C#N)c1 IWRIHOVBGLAUMI-MUUNZHRXSA-N 0.000 description 1
- KXGKLVDEBRIQFO-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2-c2n[n](C)cn2)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C KXGKLVDEBRIQFO-WJOKGBTCSA-N 0.000 description 1
- QLKKUCMECFGJPW-WJOKGBTCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N QLKKUCMECFGJPW-WJOKGBTCSA-N 0.000 description 1
- HFJWYIRBCXJXCP-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1C#N)ccc1OC Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1C#N)ccc1OC HFJWYIRBCXJXCP-GDLZYMKVSA-N 0.000 description 1
- NZGODKRGDVEIHO-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(N2CCC3(COC3)CC2)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(N2CCC3(COC3)CC2)=N)c1N NZGODKRGDVEIHO-MUUNZHRXSA-N 0.000 description 1
- UGQWPDPHUJLHHG-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2)ccc2OC(C)C)=N)c1N UGQWPDPHUJLHHG-SSEXGKCCSA-N 0.000 description 1
- JCMIVDUCQQWBKF-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(/N=C\NC)=N)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N JCMIVDUCQQWBKF-SSEXGKCCSA-N 0.000 description 1
- WKBRCYUPJGVUHK-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)ccc1C#N WKBRCYUPJGVUHK-GDLZYMKVSA-N 0.000 description 1
- YHTVCPYYJHUOHR-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)cnc1OC(C)C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c(cc1)cnc1OC(C)C YHTVCPYYJHUOHR-GDLZYMKVSA-N 0.000 description 1
- NDYZERRPOSDION-GDLZYMKVSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1cccc(C#N)c1 Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc1)cc2c1[nH]nc2-c1cccc(C#N)c1 NDYZERRPOSDION-GDLZYMKVSA-N 0.000 description 1
- JKQXUYKLHYCEJL-MUUNZHRXSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1C#N)ccc1OC Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1C#N)ccc1OC JKQXUYKLHYCEJL-MUUNZHRXSA-N 0.000 description 1
- NNJLNLUKNJWBQJ-SSEXGKCCSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c(cc2)ccc2C(O2)=NN(C)C2=O)=O)CC1)=O)c(cc12)ccc1[nH]nc2-c(cc1OC)ccc1C#[N]C NNJLNLUKNJWBQJ-SSEXGKCCSA-N 0.000 description 1
- PXLRXJWIKHLWRW-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(-c3n[n](C)cn3)[s]2)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(-c3n[n](C)cn3)[s]2)=O)CC1)=O)c(cc1)cc(C(c(cc2)ccc2OC(C)C)=N)c1N PXLRXJWIKHLWRW-AREMUKBSSA-N 0.000 description 1
- AJMAZXQDNAHQJZ-AREMUKBSSA-N CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(/C(/N=C\NC)=N/C)[s]2)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N Chemical compound CCN(C([C@H]1CN(CC(N(CC2)CC=C2c2ncc(/C(/N=C\NC)=N/C)[s]2)=O)CC1)=O)c(cc1)nc(C(c(cc2OC)ccc2OC(C)C)=N)c1N AJMAZXQDNAHQJZ-AREMUKBSSA-N 0.000 description 1
- VGWBWSNFRKSYAS-UHFFFAOYSA-N C[n]1nc(-c2ccc(C(CC3)CCN3C(CCl)=O)cc2)nc1 Chemical compound C[n]1nc(-c2ccc(C(CC3)CCN3C(CCl)=O)cc2)nc1 VGWBWSNFRKSYAS-UHFFFAOYSA-N 0.000 description 1
- ONIFNICATWBCHW-UHFFFAOYSA-N Cc1n[n](C)cn1 Chemical compound Cc1n[n](C)cn1 ONIFNICATWBCHW-UHFFFAOYSA-N 0.000 description 1
- KGSDBFAYJUPWSS-UHFFFAOYSA-N O=C(c1ccccc1)ON(CC1)CC1(CCN1)C1=O Chemical compound O=C(c1ccccc1)ON(CC1)CC1(CCN1)C1=O KGSDBFAYJUPWSS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021154677A JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404668P | 2016-10-05 | 2016-10-05 | |
| US62/404,668 | 2016-10-05 | ||
| PCT/US2017/054865 WO2018067512A1 (en) | 2016-10-05 | 2017-10-03 | Spirocyclic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Division JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534261A JP2019534261A (ja) | 2019-11-28 |
| JP2019534261A5 JP2019534261A5 (enExample) | 2020-11-12 |
| JP6949952B2 true JP6949952B2 (ja) | 2021-10-13 |
Family
ID=61831517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518440A Expired - Fee Related JP6949952B2 (ja) | 2016-10-05 | 2017-10-03 | スピロ環化合物 |
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021154677A Pending JP2021193138A (ja) | 2016-10-05 | 2021-09-22 | スピロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10934304B2 (enExample) |
| EP (1) | EP3523306A4 (enExample) |
| JP (2) | JP6949952B2 (enExample) |
| KR (1) | KR20190075931A (enExample) |
| CN (1) | CN109890827A (enExample) |
| AU (1) | AU2017339890A1 (enExample) |
| BR (1) | BR112019005305A2 (enExample) |
| CA (1) | CA3037064A1 (enExample) |
| IL (1) | IL265752A (enExample) |
| MX (1) | MX2019003938A (enExample) |
| RU (1) | RU2019107667A (enExample) |
| TW (1) | TW201817732A (enExample) |
| WO (1) | WO2018067512A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MX379622B (es) | 2015-04-03 | 2025-03-11 | Recurium Ip Holdings Llc | Compuestos espirociclicos |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| CN112654396B (zh) * | 2018-09-07 | 2025-07-01 | 默克专利股份公司 | 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| AU2024374279A1 (en) * | 2023-10-31 | 2026-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of mutant braf |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA84930C2 (ru) | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
| KR101417136B1 (ko) * | 2005-12-13 | 2014-08-07 | 머크 샤프 앤드 돔 코포레이션 | Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물 |
| WO2008063609A2 (en) | 2006-11-17 | 2008-05-29 | Polyera Corporation | Diimide-based semiconductor materials and methods of preparing and using the same |
| CA2691417A1 (en) * | 2007-06-18 | 2008-12-24 | Schering Corporation | Heterocyclic compounds and use thereof as erk inhibitors |
| EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| US8664213B2 (en) * | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
| CN103130775B (zh) | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
| US8987264B2 (en) | 2012-11-09 | 2015-03-24 | Bristol-Myers Squibb Company | 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C |
| US9447026B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| US9879029B2 (en) | 2014-12-22 | 2018-01-30 | Eli Lilly And Company | ERK inhibitors |
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| MX379622B (es) | 2015-04-03 | 2025-03-11 | Recurium Ip Holdings Llc | Compuestos espirociclicos |
-
2017
- 2017-10-03 AU AU2017339890A patent/AU2017339890A1/en not_active Abandoned
- 2017-10-03 EP EP17858989.1A patent/EP3523306A4/en not_active Withdrawn
- 2017-10-03 CN CN201780067175.6A patent/CN109890827A/zh active Pending
- 2017-10-03 KR KR1020197012021A patent/KR20190075931A/ko not_active Ceased
- 2017-10-03 BR BR112019005305A patent/BR112019005305A2/pt not_active Application Discontinuation
- 2017-10-03 US US16/336,854 patent/US10934304B2/en not_active Expired - Fee Related
- 2017-10-03 MX MX2019003938A patent/MX2019003938A/es unknown
- 2017-10-03 JP JP2019518440A patent/JP6949952B2/ja not_active Expired - Fee Related
- 2017-10-03 RU RU2019107667A patent/RU2019107667A/ru not_active Application Discontinuation
- 2017-10-03 WO PCT/US2017/054865 patent/WO2018067512A1/en not_active Ceased
- 2017-10-03 CA CA3037064A patent/CA3037064A1/en not_active Abandoned
- 2017-10-05 TW TW106134299A patent/TW201817732A/zh unknown
-
2019
- 2019-04-01 IL IL265752A patent/IL265752A/en unknown
-
2020
- 2020-12-18 US US17/127,710 patent/US20210115058A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154677A patent/JP2021193138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3037064A1 (en) | 2018-04-12 |
| TW201817732A (zh) | 2018-05-16 |
| CN109890827A (zh) | 2019-06-14 |
| EP3523306A1 (en) | 2019-08-14 |
| JP2021193138A (ja) | 2021-12-23 |
| EP3523306A4 (en) | 2020-05-06 |
| US20210115058A1 (en) | 2021-04-22 |
| WO2018067512A1 (en) | 2018-04-12 |
| MX2019003938A (es) | 2019-06-10 |
| NZ751398A (en) | 2021-03-26 |
| RU2019107667A (ru) | 2020-11-06 |
| AU2017339890A1 (en) | 2019-04-11 |
| WO2018067512A8 (en) | 2018-11-01 |
| US10934304B2 (en) | 2021-03-02 |
| IL265752A (en) | 2019-06-30 |
| JP2019534261A (ja) | 2019-11-28 |
| KR20190075931A (ko) | 2019-07-01 |
| RU2019107667A3 (enExample) | 2021-01-27 |
| US20200207776A1 (en) | 2020-07-02 |
| BR112019005305A2 (pt) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6949952B2 (ja) | スピロ環化合物 | |
| US12264147B2 (en) | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | |
| US10493060B2 (en) | Spirocyclic compounds | |
| JP2018158942A (ja) | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 | |
| US20190071416A1 (en) | Compounds for treatment of cancer and epigenetics | |
| KR20210153051A (ko) | 매크로사이클릭 화합물 | |
| NZ751398B2 (en) | Spirocyclic compounds | |
| TW202126639A (zh) | 吡咯啶基系化合物 | |
| HK1256671B (en) | Spirocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20190605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200930 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200930 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210819 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210824 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210922 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6949952 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |